These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14511643)

  • 41. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
    Mest HJ; Mentlein R
    Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
    Ahrén B; Hughes TE
    Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
    Islam MS; Rahman SA; Mirzaei Z; Islam KB
    Life Sci; 2005 Jan; 76(11):1239-48. PubMed ID: 15642594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
    Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration.
    Salaga M; Mokrowiecka A; Zielinska M; Malecka-Panas E; Kordek R; Kamysz E; Fichna J
    J Pharmacol Exp Ther; 2017 Oct; 363(1):92-103. PubMed ID: 28724693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
    McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
    Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.
    Deacon CF; Hughes TE; Holst JJ
    Diabetes; 1998 May; 47(5):764-9. PubMed ID: 9588448
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.
    Carr RD; Larsen MO; Jelic K; Lindgren O; Vikman J; Holst JJ; Deacon CF; Ahrén B
    J Clin Endocrinol Metab; 2010 Feb; 95(2):872-8. PubMed ID: 20008019
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
    Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
    Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
    Oeseburg H; de Boer RA; Buikema H; van der Harst P; van Gilst WH; Silljé HH
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1407-14. PubMed ID: 20448207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.
    Mentlein R
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):443-52. PubMed ID: 19748062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation.
    Kim DM; Chu SH; Kim S; Park YW; Kim SS
    BMB Rep; 2009 Apr; 42(4):212-6. PubMed ID: 19403044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.
    Willard JR; Barrow BM; Zraika S
    Diabetologia; 2017 Apr; 60(4):701-708. PubMed ID: 27933334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cloning and functional expression of dipeptidyl peptidase IV from the ruminal bacterium Prevotella albensis M384(T).
    Walker ND; McEwan NR; Wallace RJ
    Microbiology (Reading); 2003 Aug; 149(Pt 8):2227-2234. PubMed ID: 12904562
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
    Stremenová J; Mares V; Lisá V; Hilser M; Krepela E; Vanicková Z; Syrucek M; Soula O; Sedo A
    Int J Oncol; 2010 Feb; 36(2):351-8. PubMed ID: 20043068
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hindbrain DPP-IV inhibition improves glycemic control and promotes negative energy balance.
    Mietlicki-Baase EG; McGrath LE; Koch-Laskowski K; Krawczyk J; Pham T; Lhamo R; Reiner DJ; Hayes MR
    Physiol Behav; 2017 May; 173():9-14. PubMed ID: 28119159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.